ENTA Overview

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Wall Street analysts forecast ENTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTA is18.50 USD with a low forecast of 17.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Enanta Pharmaceuticals Inc revenue for the last quarter amounts to 17.16M USD, increased 14.96

Enanta Pharmaceuticals Inc. EPS for the last quarter amounts to -0.45 USD, decreased -57.55

Enanta Pharmaceuticals Inc (ENTA) has 120 emplpoyees as of July 08 2026.

Today ENTA has the market capitalization of 414.66M USD.